黄热病减毒活疫苗:一种非常成功的减毒活疫苗,但我们仍面临控制该疾病的难题
黄热病是原型出血热,至少250年来一直是主要公共卫生问题。1930年代开发的17D株减毒活疫苗极其有效,对控制该病至关重要;黄热病是目前唯一根据《国际卫生条例》要求国际疫苗接种证书的疾病。尽管疫苗成功,2016年安哥拉和刚果民主共和国出现疫苗供应不足,首次紧急批准分次剂量接种;未来需持续警惕并改善供需。
要点
- 黄热病至少250年来是主要公共卫生问题,17D株减毒活疫苗在控制该病中起关键作用。
- 黄热病是目前唯一根据《国际卫生条例》要求国际疫苗接种证书的疾病。
- 2016年安哥拉和刚果民主共和国疫苗供应不足,首次紧急批准分次剂量接种。
核心结论
- 黄热病减毒活疫苗非常成功,但未来仍需持续警惕并改善疫苗供应和需求。
研究设计与样本
- 原文为综述,未报告系统检索范围。
主要发现
- 黄热病被视为原型出血热,至少250年来一直是主要公共卫生问题。
- 17D株减毒活疫苗于1930年代开发,对控制黄热病至关重要;没有疫苗,黄热病病毒会被视为生物安全四级病原体。
- 黄热病是目前唯一根据《国际卫生条例》要求国际疫苗接种证书的疾病。
- 2016年安哥拉和刚果民主共和国出现疫苗供应不足,首次紧急批准分次剂量接种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Yellow fever (YF) is regarded as the original hemorrhagic fever and has been a major public health problem for at least 250years. A very effective live attenuated vaccine, strain 17D, was developed in the 1930s and this has proved critical in the control of the disease. There is little doubt that without the vaccine, YF virus would be considered a biosafety level 4 pathogen. Significantly, YF is currently the only disease where an international vaccination certificate is required under the International Health Regulations. Despite having a very successful vaccine, there are occasional issues of supply and demand, such as that which occurred in Angola and Democratic Republic of Congo in 2016 when there was insufficient vaccine available. For the first time fractional dosing of the vaccine was approved on an emergency basis. Thus, continued vigilance and improvements in supply and demand are needed in the future.
引用
- Barrett ADT. Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease. Vaccine. 2017. PMID: 28366605. doi:10.1016/j.vaccine.2017.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。